Raynaud Phenomenon and Peripheral Vascular Disease

Molecular and Cellular Mechanisms

• Endothelial dysfunction and reduced nitric oxide (NO) bioavailability: Impaired endothelial-derived NO production and increased phosphodiesterase-5 activity lead to diminished vasodilation capacity. In secondary Raynaud phenomenon associated with systemic sclerosis, circulating anti-endothelial cell antibodies and TGF-β activation perpetuate endothelial injury and dysfunction, reducing prostacyclin (PGI2) production and increasing endothelin-1 (ET-1) production by damaged endothelium.

• Exaggerated alpha-2 adrenergic vasoconstriction: Digital arteries and arterioles express increased alpha-2A adrenergic receptors with enhanced sensitivity to catecholamine-mediated vasoconstriction. Cold-induced sympathetic activation triggers disproportionate digital arterial constriction. In primary Raynaud disease, this represents a functional disorder of vascular reactivity; in secondary forms, structural arterial changes compound functional abnormality.

• Abnormal intracellular calcium handling and smooth muscle dysfunction: Vascular smooth muscle cells demonstrate altered calcium mobilization and sensitization, with excessive contraction in response to normal stimuli. Increased expression of rho kinase (ROCK) in secondary Raynaud phenomenon amplifies smooth muscle contractility independent of calcium influx, perpetuating vasospasm and promoting pathological vascular remodeling.

• Structural arterial changes in secondary Raynaud phenomenon: Progressive intimal proliferation and medial hypertrophy of digital arteries develop with chronic disease, narrowing the vascular lumen. In systemic sclerosis-associated Raynaud phenomenon, adventitial fibrosis and obliterative arteriopathy create structural stenosis superimposed on functional vasospasm, explaining digital ischemic ulceration and tissue necrosis.

• Platelet dysfunction and microthrombi formation: Elevated platelet reactivity, increased von Willebrand factor levels, and abnormal platelet aggregation occur in secondary Raynaud phenomenon, promoting microthrombus formation within narrowed digital vessels during vasospastic episodes, compounding ischemic injury.

• Impaired fibrinolysis and increased tissue factor: Elevated PAI-1 (plasminogen activator inhibitor-1) and tissue factor expression promote prothrombotic states in secondary Raynaud phenomenon, increasing microvascular thrombosis risk during vasospastic events.

Primary (Idiopathic) Raynaud Disease

• No identifiable associated systemic disease
• Female predominance (5:1 ratio)
• Younger age of onset (typically <30 years)
• Positive family history (25-30% of cases)
• Milder clinical course with minimal tissue injury

Secondary Raynaud Phenomenon—Connective Tissue Disorders

• Systemic sclerosis (scleroderma): Most frequent secondary cause; occurs in 90% of patients with limited cutaneous systemic sclerosis and diffuse cutaneous systemic sclerosis. Pathologically associated with endothelial cell apoptosis, fibroblast activation, and collagen deposition in vessel walls
• Systemic lupus erythematosus (SLE): Occurs in 20% of SLE patients; associated with anti-SSA/Ro and anti-RNP antibodies promoting endothelial dysfunction
• Mixed connective tissue disease (MCTD): Anti-RNP antibody-positive disease; Raynaud phenomenon present in majority of patients
• Sjögren syndrome: Associated with anti-SSA/Ro and anti-SSB/La antibodies
• Rheumatoid arthritis: Occurs in 10-15% with erosive disease; associated with immune complex deposition in digital vessels

Secondary Raynaud Phenomenon—Occupational/Physical Causes

• Vibration-induced white finger (VIWF): Occupational exposure to vibrating tools (jackhammers, chain saws) causes chronic endothelial injury and accelerated atherosclerotic changes in digital arteries
• Thoracic outlet syndrome: Structural compression of subclavian artery by cervical rib or fibrous bands causes arterial stenosis and distal vasospasm

Secondary Raynaud Phenomenon—Medication-Related

• Beta-blockers: Reduce beta-2 mediated vasodilation while preserving alpha-1 adrenergic vasoconstriction
• Ergotamines and triptans: Direct digital artery vasoconstrictors
• Chemotherapeutic agents: Bleomycin, cisplatin, and taxanes cause endothelial damage and vasospasm
• Cocaine: Causes acute severe vasospasm and endothelial injury

Secondary Raynaud Phenomenon—Arterial Occlusive Diseases

• Atherosclerotic peripheral arterial disease: Chronic stenosis or occlusion of digital arteries narrows lumen, predisposing to vasospastic exacerbations and ischemic complications
• Thromboangiitis obliterans (Buerger disease): Segmental inflammatory thrombosis of small and medium vessels in young smokers; highly associated with vasospasm
• Arterial embolism: Microemboli from proximal atherosclerotic plaques or cardiac sources lodge in digital arteries
• Hypercoagulable states: Antiphospholipid syndrome, Factor V Leiden, prothrombin gene mutation promote arterial microthrombi

Risk Factors for Peripheral Vascular Disease (General)

• Advanced age
• Smoking (most significant modifiable risk factor)
• Diabetes mellitus (microvascular and macrovascular disease)
• Hypertension
• Dyslipidemia
• Chronic kidney disease (uremic toxins promote endothelial dysfunction and calcific arteriopathy)
• Male sex (except in Raynaud disease where female predominance noted)

Classic Episodic Features of Raynaud Phenomenon

• Triphasic color changes (present in ~40% of patients): White (pallor from initial vasospasm), then blue (cyanosis from deoxygenation of static blood), then red (hyperemia from reactive vasodilation). Color changes typically demarcate at the level of individual digits or portions thereof, creating characteristic line of demarcation between affected and normal skin.
• Digital pain and paresthesias: Ischemic pain develops during vasospastic episodes; paresthesias result from ischemic nerve conduction block. Pain intensity correlates with severity of vasospasm and degree of ischemic insult.
• Episodes triggered by cold exposure or emotional stress: Typical episode duration 15-20 minutes; resolution occurs with rewarming or stress relief
• Asymmetrical involvement: Digits of hands most commonly affected; feet involved in ~40% of patients. Typically spares thumb and thenar eminence due to different vascular anatomy (more abundant collateral supply from radial artery)

Physical Examination Findings

• Normal examination between episodes in primary Raynaud disease; skin, nails, and pulses appear entirely normal
• Digital ulcers and gangrene (pathognomonic for secondary Raynaud phenomenon): Painful, punched-out ulcers typically on fingertips or over bony prominences (knuckles, nail beds); result from chronic ischemia superimposed on acute vasospastic episodes. Tissue necrosis creates sharply demarcated areas of coagulative necrosis with surrounding zone of granulation tissue
• Digital pitting scars (atrophic scars after healed ulcers): Indicate previous tissue loss from severe ischemia
• Cutaneous sclerosis of fingers (in systemic sclerosis-associated Raynaud): Hidebound, fibrotic skin with loss of normal wrinkles and restricted joint mobility; reflects dermal and subcutaneous fibrosis
• Dilated capillaries and telangiectasias (especially periungual): Visible dilated capillary loops at nail bed margins indicate chronic vascular injury and reactive capillary hyperplasia
• Fingernail changes: Nail ridging, pitting, dystrophy, and onycholysis develop from recurrent ischemic insults to nail matrix
• Loss of digital pulses or diminished pulses: Indicates structural arterial stenosis/occlusion in secondary disease (absent in primary Raynaud disease with patent digital arteries)
• Coolness of digits: Objective finding during vasospastic episode; thermography may show decreased digital temperature

Laboratory and Imaging Correlates

• Capillaroscopy findings: In primary Raynaud disease, capillaries appear normal with regular architecture. In secondary Raynaud phenomenon associated with systemic sclerosis, scleroderma pattern shows giant dilated capillaries, capillary loss (dropout), and ramified (bushy) abnormal capillaries reflecting endothelial injury and reactive angiogenesis
• Elevated inflammatory markers: Elevated ESR and CRP may be present in secondary Raynaud phenomenon due to underlying connective tissue disease
• Autoantibody positivity: ANA positivity, anti-centromere antibody (ACA), anti-topoisomerase I (anti-Scl-70), anti-RNA polymerase III in systemic sclerosis; anti-Sm and anti-dsDNA in SLE; anti-RNP in MCTD
• Angiography findings in advanced secondary disease: Digital artery stenosis, segmental occlusion, dilated collateral vessels, "corkscrew" pattern of irregular vessel walls reflecting endothelial damage and remodeling
• Ultrasound and CT angiography: Demonstrate patency status of digital arteries; may reveal structural stenosis

Clinical Diagnosis—Primary Raynaud Disease

Clinical Diagnosis—Secondary Raynaud Phenomenon

Serological Testing

• ANA by immunofluorescence: Screening test for underlying connective tissue disease; present in ~95% of systemic sclerosis, ~95% of SLE, ~90% of MCTD, ~60% of Sjögren syndrome; absent in primary Raynaud disease
• Anti-centromere antibody (ACA): Highly specific for limited cutaneous systemic sclerosis (80-90% sensitivity); rare in other connective tissue diseases
• Anti-topoisomerase I (anti-Scl-70) antibody: Highly specific for diffuse cutaneous systemic sclerosis; associated with early interstitial lung disease and progressive renal involvement
• Anti-RNA polymerase III antibody: Associated with diffuse cutaneous systemic sclerosis, scleroderma renal crisis, and poor prognosis
• Anti-RNP antibody: Present in MCTD (95% sensitivity) and SLE; associated with more severe Raynaud phenomenon
• Anti-SSA/Ro and anti-SSB/La: Associated with Sjögren syndrome and SLE
• ESR and CRP: May be elevated in systemic sclerosis with active disease; helpful to distinguish secondary Raynaud from primary form

Histopathological Findings (Digital Artery Biopsy—Rarely Performed but Pathologically Important)

• Primary Raynaud disease: Digital arteries show normal wall structure with patent lumens; no intimal proliferation, fibrosis, or medial hypertrophy
• Secondary Raynaud phenomenon (systemic sclerosis-associated):
• Concentric intimal fibrosis narrowing arterial lumen
• Medial hypertrophy with smooth muscle layer thickening
• Adventitial fibrosis with collagen deposition in outer vessel wall
• Endothelial cell swelling and injury with loss of endothelial integrity
• Absence of significant inflammation (distinguishes from vasculitis)
• Microthrombi may be present within narrowed lumens, especially during acute vasospastic episodes

Gross Pathology of Digital Tissue in Advanced Secondary Disease

• Digital ulcers: Punched-out defects with sharply demarcated margins; base shows coagulative necrosis with fibrin deposition; surrounding tissue demonstrates granulation tissue with neovascularization and chronic inflammatory infiltrate (lymphocytes, macrophages)
• Digital gangrene: Complete tissue necrosis with demarcation line between viable and necrotic tissue; necrotic tissue appears dark brown/black with mummification in dry gangrene or green discoloration/foul odor in wet gangrene (secondary bacterial infection)
• Digital amputation sites: Following auto-amputation or surgical amputation, stump shows healed wound with scar tissue formation

Imaging Studies

• Nailfold capillaroscopy (widefield video capillaroscopy): Gold standard for distinguishing primary from secondary Raynaud phenomenon. Normal pattern in primary disease; abnormal scleroderma pattern (giant dilated capillaries, capillary loss) in secondary disease, especially systemic sclerosis
• High-resolution CT chest: In suspected systemic sclerosis-associated Raynaud, evaluates for interstitial lung disease (ground-glass opacities, reticular patterns) and pulmonary hypertension (septal thickening)
• Digital artery duplex ultrasound: Evaluates patency of radial and ulnar arteries and digital arteries; demonstrates stenosis, occlusion, or abnormal flow patterns
• CT or MR angiography: Provides better anatomical detail of digital arterial occlusion and collateral circulation; useful in planning vascular intervention
• Thermography: Measures digital skin temperature; decreased temperature in affected digits during vasospastic episodes; may show asymmetry in secondary disease

Diagnostic Criteria—Proposed Classification

• Primary Raynaud disease: Episodes of triphasic color changes, symptom onset <30 years, no tissue necrosis/ulcers, negative/low-titer serology, normal capillaroscopy
• Secondary Raynaud phenomenon: History of underlying connective tissue disease OR ≥1 abnormality on nailfold capillaroscopy OR positive specific autoantibody (anti-centromere, anti-Scl-70, anti-RNP, anti-SSA)

Nonpharmacological Management (First-Line for Primary Disease)

• Cold avoidance: Most effective intervention; educate patients to wear insulated gloves during cold exposure and avoid ice contact. Rewarming should be gradual (avoid rapid rewarming which can trigger reactive vasodilation-induced pain)
• Stress management: Behavioral modifications, relaxation techniques, biofeedback reduce emotional trigger-induced episodes
• Smoking cessation: Smoking promotes vasoconstriction and should be discontinued

Ischemic complications of the digits

• Digital ulceration: fixed structural narrowing (intimal fibrosis) plus recurrent vasospasm drops perfusion below tissue demand; signaled by a painful punched-out fingertip ulcer. Nearly always secondary Raynaud phenomenon, most often systemic sclerosis.
• Critical digital ischemia and gangrene: superimposed microthrombosis in an already stenotic digital artery produces persistent pallor/cyanosis that does not rewarm, rest pain, and demarcated black mummified tissue. Emergency — requires urgent hospitalization, warming, IV prostacyclin analogue (e.g., iloprost) per EULAR systemic sclerosis recommendations, and vascular consultation; auto-amputation follows untreated disease.
• Secondary infection: ulcer colonization progressing to cellulitis or osteomyelitis; suspect with purulence, fever, or a probe-to-bone ulcer.

Complications of the underlying systemic disease

• Scleroderma renal crisis: abrupt malignant hypertension with microangiopathic hemolysis and acute kidney injury, most associated with anti-RNA polymerase III and high-dose glucocorticoid exposure. Emergency — treat with an ACE inhibitor (captopril, titrated for its short half-life); ACE inhibitors are contraindicated in pregnancy.
• Pulmonary arterial hypertension and interstitial lung disease: the same vasculopathy/fibrosis in the lung; signaled by exertional dyspnea with a loud P2 or restrictive PFTs with reduced DLCO.

Complications of peripheral arterial disease

• Acute limb ischemia: embolic or thrombotic occlusion producing the 6 Ps. Emergency — immediate anticoagulation and revascularization per the ACC/AHA lower extremity PAD guideline.
• Chronic limb-threatening ischemia: rest pain, nonhealing wounds, gangrene; portends amputation and high cardiovascular mortality.

Treatment-related complications

• Dihydropyridine calcium channel blockers (nifedipine, amlodipine): headache, flushing, reflex tachycardia, dependent edema, hypotension.
• PDE-5 inhibitors (sildenafil) and topical nitrates: headache and hypotension; absolute contraindication to combining nitrates with PDE-5 inhibitors.
• Endothelin receptor antagonists (bosentan, used to reduce new digital ulcers): hepatotoxicity and teratogenicity requiring monitoring and pregnancy prevention.
• Cilostazol for claudication: contraindicated in heart failure (PDE-3 inhibition).
• Digital sympathectomy: symptom recurrence over time from reinnervation.

• The buzzword triad: white → blue → red digital color change with a sharp line of demarcation, provoked by cold or stress. Sparing of the thumb favors Raynaud over other causes of digital ischemia.
• Single best next step when secondary disease is suspected: nailfold capillaroscopy plus ANA with systemic sclerosis-specific antibodies. Giant capillaries with capillary dropout (scleroderma pattern) plus a positive ANA is the highest-yield predictor of evolution to systemic sclerosis; entirely normal capillaries with negative ANA and normal ESR support primary Raynaud disease and need no further workup.
• The association examiners test: digital pitting scars or ulcers in a woman with skin thickening = systemic sclerosis. Anti-centromere → limited cutaneous disease/CREST and pulmonary hypertension; anti-Scl-70 (topoisomerase I) → diffuse disease and interstitial lung disease; anti-RNA polymerase III → scleroderma renal crisis.
• First-line drug: a dihydropyridine calcium channel blocker (nifedipine or amlodipine) for attacks frequent enough to impair function; nondrug cold avoidance and smoking cessation come first in mild primary disease.
• Drugs to stop: beta blockers, ergotamines/triptans, and sympathomimetics including cocaine — each unopposes or amplifies alpha-mediated digital vasoconstriction.
• Common distractors: acrocyanosis is continuous, painless, non-episodic cyanosis without pallor; pernio (chilblains) produces pruritic violaceous cold-injury lesions; thromboangiitis obliterans (Buerger disease) affects young heavy smokers with digit and foot involvement, migratory thrombophlebitis, and corkscrew collaterals on angiography — the treatment is absolute tobacco cessation, not vasodilators.
• PAD screening: the ankle-brachial index is the initial test; a value at or below 0.90 confirms disease, while a noncompressible, falsely elevated value in diabetes or CKD requires toe-brachial index or pulse volume recordings (ACC/AHA PAD guideline).
• Do not forget global risk reduction in PAD: high-intensity statin, antiplatelet therapy, smoking cessation, and supervised exercise therapy as first-line for claudication — PAD is a coronary-risk marker, and mortality is cardiovascular.